172 related articles for article (PubMed ID: 9436192)
1. Pure antiestrogens as a new therapy for breast cancer.
England GM; Jordan VC
Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
[TBL] [Abstract][Full Text] [Related]
2. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with pure antiestrogens.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
[TBL] [Abstract][Full Text] [Related]
4. The strategic use of antiestrogens to control the development and growth of breast cancer.
Jordan VC
Cancer; 1992 Aug; 70(4 Suppl):977-82. PubMed ID: 1638467
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
6. Hormonal treatment of advanced breast cancer.
Tellez C; Jordan VC
Surg Oncol Clin N Am; 1995 Oct; 4(4):751-77. PubMed ID: 8535909
[TBL] [Abstract][Full Text] [Related]
7. Update on endocrine therapy for breast cancer.
Buzdar AU; Hortobagyi G
Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
[TBL] [Abstract][Full Text] [Related]
8. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
Trunet P; Marty M
Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
11. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
12. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
Dellapasqua S; Castiglione-Gertsch M
Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
[TBL] [Abstract][Full Text] [Related]
13. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
14. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie A; Jelovac D; Long BJ
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
[TBL] [Abstract][Full Text] [Related]
15. [Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen].
Sonoo H; Kurebayashi J
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2289-99. PubMed ID: 8259841
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy for breast cancer: an overview.
Cheung KL
Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
18. [Antiestrogens: mechanism of action and clinical applications].
Barrón-González A; Arias-Martínez J; Castro-Romero I
Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]